Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clopidogrel Vs Aspirin Monotherapy for Secondary Prevention After Percutaneous Coronary Intervention: A Nationwide Cohort Study.

JACC. Asia·2026
Same author

Aspirin vs clopidogrel in chronic coronary syndromes: a meta-analysis of ethnic differences.

European heart journal·2026
Same author

Prehospital prediction of mechanical circulatory support during hospital stay in cardiogenic shock: The FLAG score.

Heart & lung : the journal of critical care·2026
Same author

2025 Acute Coronary Syndrome Guideline: Missing the Boat on <i>CYP2C19</i> Genotyping.

Journal of the American Heart Association·2026
Same author

Delayed Diagnosis of Infective Endocarditis-Analysis of an Endocarditis Network.

Journal of clinical medicine·2026
Same author

Assessment of chronic aortic regurgitation using end-diastolic flow reversal in the upper descending aorta: diagnostic accuracy and prediction of aortic valve surgery in a prospective echocardiography and cardiac magnetic resonance imaging study.

Echo research and practice·2026

Related Experiment Video

Updated: May 14, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Platelet function testing in patients with acute coronary syndrome.

Martin Orban1, Dirk Sibbing

  • 1Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Campus Grosshadern, Marchioninistr. 15, 81377 Munich, Germany. MartinOrban@gmail.com

Journal of Cardiovascular Translational Research
|February 12, 2013
PubMed
Summary

Personalized antiplatelet therapy using P2Y12 inhibitors in acute coronary syndrome (ACS) patients needs further study. Current evidence is limited, and optimal treatment strategies require more investigation for improved patient outcomes.

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Related Experiment Videos

Last Updated: May 14, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • P2Y12 receptor inhibitors are crucial for managing acute coronary syndrome (ACS).
  • Clopidogrel, a common inhibitor, has limitations including delayed action and variable patient response.
  • More potent inhibitors like prasugrel and ticagrelor offer improved efficacy in reducing thrombotic events.

Purpose of the Study:

  • To investigate the potential benefits of personalized antiplatelet therapy guided by platelet function monitoring in ACS patients.
  • To evaluate if tailored regimens using prasugrel, ticagrelor, and clopidogrel can improve patient outcomes.

Main Methods:

  • Review of randomized studies on personalized antiplatelet therapy based on platelet function monitoring.
  • Analysis of patient populations, primarily focusing on elective and stable coronary artery disease patients in previous studies.

Main Results:

  • Previous studies investigating personalized antiplatelet therapy based on platelet function monitoring yielded negative results regarding monitoring benefits.
  • These studies were limited by their inclusion of predominantly stable and elective patients, not ACS patients.

Conclusions:

  • Further research is warranted to determine if a tailored, platelet function-guided antiplatelet therapy can improve outcomes in ACS patients.
  • The efficacy of available P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) within a personalized treatment framework in ACS remains to be fully elucidated.